| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Reviews |
1 Whitehead Institute for Biomedical Research, Cambridge Center and 2 Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts
Requests for reprints: Robert A. Weinberg, Whitehead Institute, 9 Cambridge Center, Cambridge, MA 02142. Phone: 617-258-5176; E-mail: weinberg{at}wi.mit.edu.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
To address these issues, it is important to use experimental metastasis models that can recapitulate, at least in outline, the physiologic and pathologic conditions observed in human cancer patients. In the past, extensive effort has been devoted to introduce human metastatic carcinoma cells into mice. Surprisingly, although most such cell lines were isolated from metastases in human patients, they rarely spread from the implanted primary tissues (such as the s.c. site, the mammary gland, and the prostate) to distant organs in mice. As a result, most popular experimental mouse metastasis models rely on the introduction of tumor cells directly into the systemic circulation (such as the tail vein, portal vein, or by intracardiac injection) to establish metastases in distant organs. These approaches bypass some initial steps of metastasis, including local invasion and intravasation. In addition, simultaneous injection of large numbers of tumor cells into the circulation may not fully mimic the gradual, low-level dissemination of carcinoma cells in vivo.
| Gene Expression Profiles Associated with Metastatic Progression |
|---|
|
|
|---|
We took an unbiased gene expression profile approach to search for the signaling molecules involved in metastasis in this mouse mammary tumor metastasis system. By comparing the gene expression profiles of primary tumors derived from the four cell lines, we identified a list of specific genetic and epigenetic changes associated with their respective metastatic abilities. Several of the candidate genes identified are known players during tumor progression; and importantly, their activation indicates that the corresponding biological pathways might contribute to tumor metastasis. For example, the expression of CXCR3, a member of the CXCR chemokine receptor family, is associated with increased metastatic abilities, suggesting that the activation of chemokine signaling is essential to elicit chemotactic and invasive responses in carcinoma cells (2). Higher levels of matrix metalloproteinase-9 in metastatic cells indicates that remodeling and degradation of the extracellular matrix can promote tumor invasion and metastasis (3). Up-regulation of MENA, a protein of the Ena/VASP family that controls cell motility (4), highlights the importance of activation of cellular migratory pathways in metastatic tumor cells.
| Identification of the Transcription Factor Twist as a Key Regulator of Tumor Metastasis and an Inducer of Epithelial-Mesenchymal Transition |
|---|
|
|
|---|
Like other known players in tumorigenesis, Twist is most likely to exert the same biological activities during tumor metastasis as it does during normal development. The Twist gene was originally identified as being required for mesoderm induction in Drosophila (6, 7). In vertebrates, Twist is predominantly expressed in neural crest cells. Twist mutation in mice causes failure in cranial neural tube closure, indicating its role in proper migration and differentiation of neural crest and head mesenchymal cells (8, 9). Both mesoderm formation and neural crest development engages a cellular event termed the epithelial-mesenchymal transition (EMT), which involves the conversion of a sheet of tightly attached epithelial cells into highly mobile mesenchymal or neural crest cells. We examined the ability of Twist to induce EMT by expressing Twist in kidney and mammary epithelial cells. Indeed, ectopic expression of Twist resulted in the loss of E-cadherin-mediated cell-cell adhesion, activation of mesenchymal markers, and gain of cell motility (5). These results indicate that Twist can contribute to invasion and metastasis by promoting this latent EMT developmental program.
Our finding that Twist can induce EMT to promote tumor metastasis does not exclude the possibility that Twist might also activate additional cellular functions during tumor progression. Two studies reported that the expression of Twist could inhibit Myc-induced apoptosis in mouse embryo fibroblasts (10) and neuroblastoma cells (11). Because Twist, functioning as a basic helix-loop-helix transcription factor, could homodimerize or heterodimerize with other basic helix-loop-helix proteins, it may activate or suppress diverse downstream targets including apoptosis genes. For example, loss of cell-cell adhesions by epithelial cells normally results in apoptosis. During EMT, Twist may need to activate antiapoptotic programs in order to allow epithelial cells to convert to a mesenchymal fate while avoiding cell death.
| The Involvement of Twist in Malignant Human Tumors |
|---|
|
|
|---|
In the past year, several studies have also reported the expression of Twist in other human tumor types. High Twist expression was observed in metastatic melanoma and can serve as an independent marker to predict poor outcome in melanoma patients (15). Up-regulation of Twist was also shown to be associated with the more aggressive subtype of neuroblastomas with N-Myc amplification (11). Both melanoma and neuroblastoma are directly derived from neural crest cells. Because in vertebrates Twist functions primarily in the neural crest, it is conceivable that melanoma and neuroblastoma are very capable of reactivating Twist to achieve motility and invasiveness.
| The Twist Signaling Pathway during Normal Development and Tumor Metastasis |
|---|
|
|
|---|
B activation during mesoderm formation (16). In vertebrates, Twist expression in cranial neural crest tissues is essential for correct patterning of the neural tube (8, 9). The nuclear factor
B pathway has not been shown to be involved in mesoderm formation or neural crest development in vertebrates. Instead, the BMP, Wnt, and fibroblast growth factor pathways are known to modulate vertebrate neural crest development (17), therefore, they are potential inducing signals of Twist expression in carcinoma cells. In addition to Twist, several proteins, including transforming growth factor-ß (18) and the transcription factors Snail (19, 20), Slug (21), and Sip1 (22), have also been shown to induce the EMT program. Are these EMT-inducing signals acting individually or in a cooperative fashion to promote the EMT program? Again, their molecular actions during normal embryogenesis sheds some light. During mesoderm formation in Drosophila, Twist induces the expression of the transcription factor Snail to allow invagination and mesoderm differentiation (7). During neural crest development in vertebrates, expression of Snail and Slug occurs at the neural plate border where Twist is also expressed, and all three transcription factors play critical roles in neural crest formation (17). Based on these developmental data, it is very plausible that a number of such EMT-promoting molecules may act together as an EMT signaling network to invoke tumor invasion and metastasis.
| EMT and Tumor Metastasis |
|---|
|
|
|---|
|
Another major challenge in such studies is to identify reliable molecular markers to define cells that are undergoing EMT in human tumors. Currently, the most commonly used markers for EMT are adherens junction proteins and mesenchymal markers such as vimentin. To date, the best report of EMT in human cancers is the detection of EMT cells at the invading front of colorectal carcinomas using loss of E-cadherin expression and nuclear ß-catenin as markers (25). Because the main consequence of EMT is the acquisition of invasiveness and motility, it will be very useful to score EMT through the presence of motility-associated genes that are activated in human cancers. Indeed, the identification of the downstream effector pathways that are activated during EMT holds the promise of revealing new diagnostic markers of advanced malignancy and, quite possibly, novel targets for antimetastasis therapeutics.
| Acknowledgments |
|---|
Received 10/24/05. Revised 2/ 8/06. Accepted 3/ 3/06.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
E. M. Conn, K. A. Botkjaer, T. A. Kupriyanova, P. A. Andreasen, E. I. Deryugina, and J. P. Quigley Comparative Analysis of Metastasis Variants Derived from Human Prostate Carcinoma Cells: Roles in Intravasation of VEGF-Mediated Angiogenesis and uPA-Mediated Invasion Am. J. Pathol., October 1, 2009; 175(4): 1638 - 1652. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Phillips, L. D. Burgoon, and J. I. Goodman Phenobarbital Elicits Unique, Early Changes in the Expression of Hepatic Genes that Affect Critical Pathways in Tumor-Prone B6C3F1 Mice Toxicol. Sci., June 1, 2009; 109(2): 193 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q.-Q. Li, J.-D. Xu, W.-J. Wang, X.-X. Cao, Q. Chen, F. Tang, Z.-Q. Chen, X.-P. Liu, and Z.-D. Xu Twist1-Mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer Cells Clin. Cancer Res., April 15, 2009; 15(8): 2657 - 2665. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shiota, H. Izumi, A. Tanimoto, M. Takahashi, N. Miyamoto, E. Kashiwagi, A. Kidani, G. Hirano, D. Masubuchi, Y. Fukunaka, et al. Programmed Cell Death Protein 4 Down-regulates Y-Box Binding Protein-1 Expression via a Direct Interaction with Twist1 to Suppress Cancer Cell Growth Cancer Res., April 1, 2009; 69(7): 3148 - 3156. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Miele, N. Takebe, and S. P. Ivy The Cancer Stem Cell Hypothesis, Embryonic Signaling Pathways, and Therapeutics: Targeting an Elusive Concept ASCO Educational Book, January 1, 2009; 2009(1): 145 - 156. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Holder Analysis of chloroethane toxicity and carcinogenicity including a comparison with bromoethane Toxicology and Industrial Health, November 1, 2008; 24(10): 655 - 675. [Abstract] [PDF] |
||||
![]() |
G. J. Strewler Cancer Stem Cells and Bone Metastasis IBMS BoneKEy, September 1, 2008; 5(9): 308 - 322. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. O. Rodrigues, S. T. Nerlick, E. L. White, J. L. Cleveland, and M. L. King A Myc-Slug (Snail2)/Twist regulatory circuit directs vascular development Development, June 1, 2008; 135(11): 1903 - 1911. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cao, C. Chiarelli, O. Richman, K. Zarrabi, P. Kozarekar, and S. Zucker Membrane Type 1 Matrix Metalloproteinase Induces Epithelial-to-Mesenchymal Transition in Prostate Cancer J. Biol. Chem., March 7, 2008; 283(10): 6232 - 6240. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mimeault and S. K. Batra Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies Ann. Onc., October 1, 2007; 18(10): 1605 - 1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Hotz, M. Arndt, S. Dullat, S. Bhargava, H.-J. Buhr, and H. G. Hotz Epithelial to Mesenchymal Transition: Expression of the Regulators Snail, Slug, and Twist in Pancreatic Cancer Clin. Cancer Res., August 15, 2007; 13(16): 4769 - 4776. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. J. Fidler Models for Spontaneous Metastasis Cancer Res., October 1, 2006; 66(19): 9787 - 9787. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |